- Home
- GROV vs XGN Comparison
GROV vs XGN Comparison
Compare GROV & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 71.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GROV | XGN |
|---|---|---|
| Price | $1.13 | $5.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.60 | ★ $8.86 |
| AVG Volume (30 Days) | 50.6K | ★ 583.1K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $6.81 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $2.59 |
| 52 Week High | $1.60 | $12.23 |
Technical Indicators
Market Signals| Indicator | GROV | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 77.83 |
| Support Level | $1.06 | $2.68 |
| Resistance Level | $1.58 | $6.75 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 28.00 | 92.00 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.